149 related articles for article (PubMed ID: 32163849)
1. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis.
Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K
Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454
[TBL] [Abstract][Full Text] [Related]
5. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M
Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE.
Sottani C; Poggi G; Melchiorre F; Montagna B; Minoia C
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Feb; 915-916():71-8. PubMed ID: 23337906
[TBL] [Abstract][Full Text] [Related]
8. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.
Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H
Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of weekly low dose doxorubicin.
Frenay M; Milano G; Renee N; Pons D; Khater R; François E; Thyss A; Namer M
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):191-5. PubMed ID: 2702975
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib.
Zhou ZY; Wan LL; Yang QJ; Han YL; Li Y; Yu Q; Guo C; Li X
Toxicol Appl Pharmacol; 2013 Oct; 272(1):238-44. PubMed ID: 23770382
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.
Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF
Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Edwards DM; Marrari P; Efthymiopoulos C; Basileo G; Fraier D; Pianezzola E; Strolin-Benedetti M
Drug Metab Dispos; 1991; 19(5):938-45. PubMed ID: 1686240
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion.
Pfeiffer T; Krause U; Thome U; Skorzek M; Scheulen ME
Eur J Surg Oncol; 1995 Oct; 21(5):551-4. PubMed ID: 7589605
[TBL] [Abstract][Full Text] [Related]
16. In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice.
Hanušová V; Tomšík P; Kriesfalusyová L; Pakostová A; Boušová I; Skálová L
Pharmacol Rep; 2013; 65(2):445-52. PubMed ID: 23744429
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
18. Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography.
Eder AR; Chen JS; Arriaga EA
Electrophoresis; 2006 Aug; 27(16):3263-70. PubMed ID: 16915573
[TBL] [Abstract][Full Text] [Related]
19. Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs.
Lilienberg E; Dubbelboer IR; Sjögren E; Lennernäs H
J Pharm Pharmacol; 2017 Feb; 69(2):135-142. PubMed ID: 27882559
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
